At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
CHIKV VLP, adjuvantedbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV VLP], Aluminum Hydroxide Adjuvanted)
In Brief
A Phase 2 clinical trial evaluating CHIKV VLP, adjuvanted for Chikungunya Virus. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The objective of this study is to assess the safety and immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine \[CHIKV VLP\], aluminum hydroxide adjuvanted).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus
CountriesUnited States
CollaboratorsEmergent BioSolutions
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartOct 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedOct 4, 2021
Enrollment StartOct 11, 2021
Primary CompletionMay 5, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.7 years ago
Interventions
CHIKV VLP, adjuvantedbiological
Adjuvanted formulation includes aluminum hydroxide